

**FAX TRANSMITTAL  
TO THE UNITED STATES PATENT OFFICE****RECEIVED  
CENTRAL FAX CENTER****SEP 02 2004**Applicants Docket Number:  
ST01001 US NPApplicants:  
Mailliet, et alSerial No.  
10/040,370Filing Date:  
January 09, 2002

Title of Invention:

Chemical Derivatives And Their Application As Antitelomerase Agents

**CERTIFICATE OF TRANSMISSION**I hereby certify that this correspondence is being transmitted via  
facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria,  
VA 22313-1450, at (703) 872-2306, onDate of Deposit September 2, 2004Printed Name of Person Signing Certificate Maribel MenderSignature Maribel Mender**Total Number of Pages Sent: 17 pgs.**Attorney: **Balaram Gupta**Group Art Unit: **1624**  
Examiner: **Venkataraman  
Balasubramanian**TO: Mail Stop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of **Aventis Pharmaceuticals Inc.**

- |  |   |
|--|---|
| <input type="checkbox"/> Amendment, 37 CFR _____               | <input type="checkbox"/> Fee Transmittal  |
| <input type="checkbox"/> Charge deposit account, in duplicate  | <input type="checkbox"/> Petition under 37 CFR _____  |
| <input type="checkbox"/> Extension of Time Petition            | <input type="checkbox"/> Other _____  |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order | <input checked="" type="checkbox"/> Other <u>Supplemental Amendment</u><br><u>Pursuant to 37 C.F.R. § 1.121 And Reply</u><br><u>Pursuant to 37 C.F.R. § 1.116 (16 pgs.)</u> |
| <input type="checkbox"/> Maintenance Fee Transmittal           |   |

Receipt Confirmed:

Signed \_\_\_\_\_

Dated \_\_\_\_\_

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. [www.aventis.com](http://www.aventis.com)  
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)